18 shown
| # | Company | Score | Growth | Margin | Mkt cap | F |
|---|---|---|---|---|---|---|
| 1 | IBRXImmunityBio, Inc. | 100 | 668% | -310% | $9.9B | 5 |
| 2 | TARSTarsus Pharmaceuticals, Inc. | 94 | 147% | -15% | $2.8B | — |
| 3 | BEAMBeam Therapeutics Inc. | 88 | 120% | -40% | $3.6B | — |
| 4 | BCRXBIOCRYST PHARMACEUTICALS INC | 82 | 94% | -52% | $2.5B | 7 |
| 5 | HALOHALOZYME THERAPEUTICS, INC. | 76 | 38% | 23% | $9.4B | 5 |
| 6 | ADPTAdaptive Biotechnologies Corp | 71 | 55% | -17% | $3.4B | 6 |
| 7 | GLUEMonte Rosa Therapeutics, Inc. | 65 | 64% | -31% | $2.0B | — |
| 8 | ADMAADMA BIOLOGICS, INC. | 59 | 20% | 32% | $2.1B | 5 |
| 9 | RGENREPLIGEN CORP | 53 | 16% | 7% | $8.0B | 7 |
| 10 | VCELVericel Corp | 47 | 16% | 6% | $2.4B | 8 |
| 11 | QGENQIAGEN N.V. | 41 | 6% | 20% | $8.3B | 7 |
| 12 | TWSTTwist Bioscience Corp | 35 | 20% | -20% | $6.2B | 4 |
| 13 | IMVTImmunovant, Inc. | 29 | 229% | -1040% | $8.0B | — |
| 14 | KYMRKymera Therapeutics, Inc. | 24 | -17% | -794% | $9.3B | 4 |
| 15 | RXRXRECURSION PHARMACEUTICALS, INC. | 18 | 27% | -863% | $2.0B | 4 |
| 16 | RLAYRelay Therapeutics, Inc. | 12 | 53% | -2554% | $4.1B | — |
| 17 | CGONCG Oncology, Inc. | 6 | 255% | -3683% | $6.2B | — |
| 18 | CRSPCRISPR Therapeutics AG | 0 | -91% | -13857% | $5.9B | — |
Ranked by percentile of (0.6 × revenue growth + 0.4 × net margin) within the Biotechnology · mid-cap cohort (18 companies). Score 0–100. Click a column to re-sort; Best/Worst flip the cohort ranking.